These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11891276)

  • 21. Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane.
    Loo TW; Clarke DM
    J Biol Chem; 2000 Dec; 275(50):39272-8. PubMed ID: 11013259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments.
    Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2002 Aug; 277(31):27585-8. PubMed ID: 12070134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of proline residues in the core cytoplasmic and transmembrane regions of multidrug resistance protein 1 (MRP1/ABCC1) important for transport function, substrate specificity, and nucleotide interactions.
    Koike K; Conseil G; Leslie EM; Deeley RG; Cole SP
    J Biol Chem; 2004 Mar; 279(13):12325-36. PubMed ID: 14722114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Q-loop disengages from the first intracellular loop during the catalytic cycle of the multidrug ABC transporter BmrA.
    Dalmas O; Orelle C; Foucher AE; Geourjon C; Crouzy S; Di Pietro A; Jault JM
    J Biol Chem; 2005 Nov; 280(44):36857-64. PubMed ID: 16107340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains.
    Liu R; Sharom FJ
    Biochemistry; 1996 Sep; 35(36):11865-73. PubMed ID: 8794769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence.
    Kast C; Canfield V; Levenson R; Gros P
    J Biol Chem; 1996 Apr; 271(16):9240-8. PubMed ID: 8621583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type protein.
    Taylor AM; Storm J; Soceneantu L; Linton KJ; Gabriel M; Martin C; Woodhouse J; Blott E; Higgins CF; Callaghan R
    Br J Pharmacol; 2001 Dec; 134(8):1609-18. PubMed ID: 11739236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein.
    Sauna ZE; Ambudkar SV
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2515-20. PubMed ID: 10716986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein.
    Loo TW; Clarke DM
    J Biol Chem; 2002 Nov; 277(46):44332-8. PubMed ID: 12223492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-function relationships of multidrug resistance P-glycoprotein.
    Pajeva IK; Globisch C; Wiese M
    J Med Chem; 2004 May; 47(10):2523-33. PubMed ID: 15115395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity.
    Julien M; Gros P
    Biochemistry; 2000 Apr; 39(15):4559-68. PubMed ID: 10758006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of residues in the drug-binding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane.
    Loo TW; Clarke DM
    J Biol Chem; 1999 Dec; 274(50):35388-92. PubMed ID: 10585407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle.
    Qu Q; Russell PL; Sharom FJ
    Biochemistry; 2003 Feb; 42(4):1170-7. PubMed ID: 12549939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conformational changes of P-glycoprotein by nucleotide binding.
    Wang G; Pincheira R; Zhang M; Zhang JT
    Biochem J; 1997 Dec; 328 ( Pt 3)(Pt 3):897-904. PubMed ID: 9396736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human P-glycoprotein is active when the two halves are clamped together in the closed conformation.
    Loo TW; Bartlett MC; Clarke DM
    Biochem Biophys Res Commun; 2010 May; 395(3):436-40. PubMed ID: 20394729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Catalytic mechanism of P-glycoprotein.
    Senior AE
    Acta Physiol Scand Suppl; 1998 Aug; 643():213-8. PubMed ID: 9789563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
    Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
    Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Both P-glycoprotein nucleotide-binding sites are catalytically active.
    Urbatsch IL; Sankaran B; Bhagat S; Senior AE
    J Biol Chem; 1995 Nov; 270(45):26956-61. PubMed ID: 7592942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residue G346 in transmembrane segment six is involved in inter-domain communication in P-glycoprotein.
    Storm J; O'Mara ML; Crowley EH; Peall J; Tieleman DP; Kerr ID; Callaghan R
    Biochemistry; 2007 Sep; 46(35):9899-910. PubMed ID: 17696319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P glycoprotein and the mechanism of multidrug resistance.
    Váradi A; Szakács G; Bakos E; Sarkadi B
    Novartis Found Symp; 2002; 243():54-65; discussion 65-8, 180-5. PubMed ID: 11990782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.